All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Stenoparib
Therapeutic Area: Infections and Infectious Diseases Product Name: 2X-121
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2021
Details:
The current and planned in-vitro studies, focusing on SARS-CoV-2 lineage B.1.1.7 and B.1.351, follow previous positive pre-clinical test results with stenoparib as a treatment of SARS-CoV-2 published in the peer-review journal mBio.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Stenoparib
Therapeutic Area: Infections and Infectious Diseases Product Name: 2X-121
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2021
Details:
Based on the previous positive pre-clinical test results with stenoparib as a treatment of SARS-CoV-2, Allarity Therapeutics will now test the similar ability of stenoparib to block the infection and replication of SARS-CoV-2 lineage B.1.1.7.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Stenoparib
Therapeutic Area: Infections and Infectious Diseases Product Name: 2X-121
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2020
Details:
Oncology Venture plans to advance Stenoparib into human clinical trials as a potential therapy for COVID-19. Stenoparib (2X-121) is a novel small molecule, targeted inhibitor of Poly ADP-Ribose Polymerase, a key DNA damage repair enzyme active in cancer cells.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CLP based Covid-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Bavarian Nordic
Deal Size: Undisclosed Upfront Cash: $4.6 million
Deal Type: Collaboration July 22, 2020
Details:
Bavarian Nordic has been granted license of AdaptVac’s proprietary capsid virus like particle (cVLP) technology for coronaviruses, including the COVID-19 indication.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Niclosamide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Institut Pasteur Korea
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 12, 2020
Details:
UNION therapeutics launch of a program to test an optimized salt form of niclosamide as a treatment of COVID-19, in collaboration with Institut Pasteur Korea.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
